In Brief: Sulzer Medica's Res-Q
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Medica's Res-Q: Firm's Sulzer Intermedics division launches the Res-Q Micron ADvantage implantable cardioverter defibrillator following FDA approval March 17. The ICD offers an "atrial discrimination" system to distinguish between ventricular and non-ventricular disorders, and is the first product to use both atrial and ventricular data to determine therapeutic regimen, the firm says. Micron ADvantage's features include storage capacity for data from both cardiac chambers, a programmable lead-to-can configuration, fibrillation confirmation, and automatic gain control..